Drug Profile
Ivacaftor - Vertex Pharmaceuticals
Alternative Names: IVA; Kalydeco; Potentiator VX-770; VRT 813077; VX-770Latest Information Update: 27 Feb 2024
Price :
$50
*
At a glance
- Originator Cystic Fibrosis Foundation Therapeutics; Vertex Pharmaceuticals
- Developer Vertex Pharmaceuticals
- Class Amides; Aminophenols; Quinolones; Small molecules
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cystic fibrosis
- Phase II Chronic obstructive pulmonary disease
Most Recent Events
- 23 Feb 2024 The CHMP of EMA adopts a positive opinion recommending expansion of usage of ivacaftor for treatment of Cystic fibrosis (In infants aged 1-4 months)
- 02 Oct 2023 Vertex Pharmaceuticals completes a phase III trial for Cystic fibrosis (In neonates, In infants, In children) in USA, Australia, Canada, Germany, Ireland and United Kingdom (NCT03277196)
- 03 May 2023 The US FDA approves ivacaftor for Cystic fibrosis (In infants aging 1 month to less than four months) in USA (PO)